black box warning for glp 1 agonists Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records dpp 4 inhibitor with

black box warning for glp 1 agonists Incidence of hematologic malignancies and mortality associated with GLP-1 receptor agonist and SGLT2 inhibitor use in type 2 diabetes mellitus: results of a retrospective cohort study of electronic health records dpp 4 inhibitor with

dpp 4 inhibitor with glp 1 Dipeptidyl peptidase-4 dpp-4 inhibitors and glp-1 agonists –

A 2018 meta-analysis found no favorable effect of DPP-4 inhibitors on all-cause mortality, cardiovascular mortality, myocardial infarction or stroke in patients with type 2 diabetes

2 Data show that more than 50% of patients started on monotherapy will require a second medication to control diabetes after three years